|
1
|
Van Vlierberghe P, van Grotel M, Beverloo
HB, Lee C, Helgason T, Buijs-Gladdines J, Passier M, van Wering ER,
Veerman AJ, Kamps WA, et al: The cryptic chromosomal deletion
del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric
T-cell acute lymphoblastic leukemia. Blood. 108:3520–3529. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boehm T, Foroni L, Kaneko Y, Perutz MF and
Rabbitts TH: The rhombotin family of cysteine-rich LIM-domain
oncogenes: Distinct members are involved in T-cell translocations
to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci USA.
88:4367–4371. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamada Y, Warren AJ, Dobson C, Forster A,
Pannell R and Rabbitts TH: The T cell leukemia LIM protein Lmo2 is
necessary for adult mouse hematopoiesis. Proc Natl Acad Sci USA.
95:3890–3895. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamada Y, Pannell R, Forster A and
Rabbitts TH: The oncogenic LIM-only transcription factor Lmo2
regulates angiogenesis but not vasculogenesis in mice. Proc Natl
Acad Sci USA. 97:320–324. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nam CH and Rabbitts TH: Role of LMO2 in
the development and in T cell leukemia after chromosomal
translocation or retroviral insertion. Mol Ther. 13:15–25. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Natkunam Y, Zhao S, Mason DY, Chen J,
Taidi B, Jones M, Hammer AS, Dutoit Hamilton S, Lossos IS and Levy
R: The oncoprotein LMO2 is expressed in normal germinal center B
cells and in human B-cell lymphomas. Blood. 109:1636–1642. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Royer-Pokora B, Loos U and Ludwig WD:
TTG-2, a new gene encoding a cysteine-rich protein with the LIM
motif, is overexpressed in acute T-cell leukaemia with the
t(11;14)(p13;q11). Oncogene. 6:1887–1893. 1991.PubMed/NCBI
|
|
8
|
McCormack MP and Rabbitts TH: Activation
of the T-cell oncogene LMO2 after gene therapy for X-linked severe
combined immunodeficiency. N Engl J Med. 350:913–922. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dong WF, Billia F, Atkins HL, Iscove NN
and Minden MD: Expression of rhombotin 2 in normal and leukaemic
haemopoietic cells. Br J Haematol. 93:280–286. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferrando AA, Neuberg DS, Staunton J, Loh
ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland
DG, et al: Gene expression signatures define novel oncogenic
pathways in T cell acute lymphoblastic leukemia. Cancer Cell.
1:75–87. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Royer-Pokora B, Rogers M, Zhu TH,
Schneider S, Loos U and Bölitz U: The TTG-2⁄RBTN2 T cell oncogene
encodes two alternative transcripts from two promoters: The distal
promoter is removed by most 11p13 translocations in acute T cell
leukaemia's (T-ALL). Oncogene. 10:1353–1360. 1995.PubMed/NCBI
|
|
12
|
Hammond SM, Crable SC and Anderson KP:
Negative regulatory elements are present in the human LMO2 oncogene
and may contribute to its expression in leukemia. Leuk Res.
29:89–97. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hacein-Bey-Abina S, Von Kalle C, Schmidt
M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS,
Pawliuk R, Morillon E, et al: LMO2-associated clonal T cell
proliferation in two patients after gene therapy for SCID-X1.
Science. 302:415–419. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Howe SJ, Mansour MR, Schwarzwaelder K,
Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K,
Chatters SJ, de Ridder D, et al: Insertional mutagenesis combined
with acquired somatic mutations causes leukemogenesis following
gene therapy of SCID-X1 patients. J Clin Invest. 118:3143–3150.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu C and Dunbar CE: Stem cell gene
therapy: The risks of insertional mutagenesis and approaches to
minimize genotoxicity. Front Med. 5:356–371. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fisch P, Boehm T, Lavenir I, Larson T,
Arno J, Forster A and Rabbitts TH: T-cell acute lymphoblastic
lymphoma induced in transgenic mice by the RBTN1 and RBTN2
LIM-domain genes. Oncogene. 7:2389–2397. 1992.PubMed/NCBI
|
|
17
|
Patel JL, Pournazari P, Haggstrom SJ,
Kosari F, Shabani-Rad MT, Natkunam Y and Mansoor A: LMO2 (LIM
domain only 2) is expressed in a subset of acute myeloid leukaemia
and correlates with normal Karyotype. Histopathology. 64:226–233.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sonmez M, Akagun T, Cobanoglu U, Topbas M,
Erkut N, Yilmaz M, Ovali E and Omay SB: Effect of LMO2 protein
expression on survival in chronic myeloid leukemia patients treated
with imatinib mesylate. Hematology. 14:220–223. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakata K, Ohuchida K, Nagai E, Hayashi A,
Miyasaka Y, Kayashima T, Yu J, Aishima S, Oda Y, Mizumoto K, et al:
LMO2 is a novel predictive marker for a better prognosis in
pancreatic cancer. Neoplasia. 11:712–719. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lossos IS, Czerwinski DK, Alizadeh AA,
Wechser MA, Tibshirani R, Botstein D and Levy R: Prediction of
survival in diffuse large-B-cell lymphoma based on the expression
of six genes. N Engl J Med. 350:1828–1837. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cobanoglu U, Sonmez M, Ozbas HM, Erkut N
and Can G: The expression of LMO2 protein in acute B-cell and
myeloid leukemia. Hematology. 15:132–134. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Malumbres R, Fresquet V, Roman-Gomez J,
Bobadilla M, Robles EF, Altobelli GG, Calasanz MJ, Smeland EB,
Aznar MA, Agirre X, et al: LMO2 expression reflects the different
stages of blast maturation and genetic features in B-cell acute
lymphoblastic leukemia and predicts clinical outcome. Hematologica.
96:980–986. 2011. View Article : Google Scholar
|
|
23
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW: WHO Classification of
Tumors of Haematopoietic and Lymphoid Tissues. 2:(4th). Lyon,
France: IARC. 2008.
|
|
24
|
Ludwig WD, Rieder H, Bartram CR, Heinze B,
Schwartz S, Gassmann W, Löffler H, Hossfeld D, Heil G, Handt S, et
al: Immunophenotypic and genotypic features, clinical
characteristics, and treatment outcome of adult pro-B acute
lymphoblastic leukaemia: Results of the German multicenter trials
GMALL 03/87 and 04/89. Blood. 92:1898–1909. 1998.PubMed/NCBI
|
|
25
|
Schwartz S, Rieder H, Schläger B,
Burmeister T, Fischer L and Thiel E: Expression of the human
homologue of rat NG2 in adult acute lymphoblastic leukemia: Close
association with MLL rearrangement and a
CD10(−)/CD24(−)/CD65s(+)/CD15(+) B-cell phenotype. Leukemia.
17:1589–1595. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Meijeerink J, Mandigers C, Van de Locht L,
Tönnissen E, Goodsaid F and Raemaekers J: A novel method to
compensate for different amplification efficiencies between patient
DNA samples in quantitative real time PCR. J Mol Diagn. 3:55–61.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Omari K, Hoosdally SJ, Tuladhar K, Karia
D, Vyas P, Patient R, Porche C and Mancini EJ: Structure of the
leukemia oncogene LMO2: Implications for the assembly of a
hematopoietic transcription factor complex. Blood. 117:2146–2156.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bach I: The LIM domain: Regulation by
association. Mech Dev. 91:5–17. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gratzinger D, Zhao S, West R, Rouse RV,
Vogel H, Gil EC, Levy R, Lossos IS and Natkunam Y: The
transcription factor LMO2 is a robust marker of vascular
endothelium and vascular neoplasms and selected other entities. Am
J Clin Pathol. 131:264–278. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pike-Overzet K, de Ridder D, Weerkamp F,
Baert MR, Verstegen MM, Brugman MH, Howe SJ, Reinders MJ, Thrasher
AJ, Wagemaker G, et al: Ectopic retroviral expression of LMO2, but
not IL2Rgamma, blocks human T-cell development from
CD34+ cells: Implications for leukemogenesis in gene
therapy. Leukemia. 21:754–763. 2007.PubMed/NCBI
|
|
31
|
Van Vlierberghe P, van Grotel M, Beverloo
HB, Lee C, Helgason T, Buijs-Gladdines J, Passier M, van Wering ER,
Veerman AJ, Kamps WA, et al: The cryptic chromosomal deletion
del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric
T-cell acute lymphoblastic leukemia. Blood. 108:3520–3529. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Van Vlierberghe P, Beverloo HB,
Buijs-Gladdines J, van Wering ER, Horstmann M, Pieters R and
Meijerink JP: Monoallelic or biallelic LMO2 expression in relation
to the LMO2 rearrangement status in pediatric T-cell acute
lymphoblastic leukemia. Leukemia. 22:1434–1437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nam CH and Rabbitts TH: The role of LMO2
in development and in T cell leukemia after chromosomal
translocation or retroviral insertion. Mol Ther. 13:15–25. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kvinlaug BT, Chan WI, Bullinger L,
Ramaswami M, Sears C, Foster D, Lazic SE, Okabe R, Benner A, Lee
BH, et al: Common and overlapping oncogenic pathways contribute to
the evolution of acute myeloid leukemias. Cancer Res. 71:4117–4129.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Calero-Nieto FJ, Joshil A, Bonadies N,
Kinston S, Chan WI, Gudgin1 E, Pridans C, Landry JR, Kikuchi J,
Huntly BJ and Gottgens B: HOX-mediated LMO2 expression in embryonic
mesoderm is recapitulated in acute leukemia. Oncogene.
32:5471–5480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al:
Distinct types of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma S, Guan XY, Beh PS, Wong KY, Chan YP,
Yuen HF, Vielkind J and Chan KW: The significance of LMO2
expression in the progression of prostate cancer. J Pathol.
211:278–285. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Natkunam Y, Farinha P, Hsi ED, Hans CP,
Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S,
et al: LMO2 protein expression predicts survival in patients with
diffuse large B-cell lymphoma treated with anthracycline-based
chemotherapy with and without rituximab. J Clin Oncol. 26:447–454.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hacein-Bey-Abina S, Garrigue A, Wang GP,
Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse
E, Beldjord K, et al: Insertional oncogenesis in 4 patients after
retrovirus-mediated gene therapy of SCID-X1. J Clin Invest.
118:3132–3142. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mullighan CG, Goorha S, Radtke I, Miller
CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds
SB, et al: Genome-wide analysis of genetic alterations in acute
lymphoblastic leukaemia. Nature. 446:758–764. 2007. View Article : Google Scholar : PubMed/NCBI
|
